Remove 2017 Remove Compounding Remove FDA
article thumbnail

7 health benefits of raspberry leaf tea

The Checkup by Singlecare

Red raspberry leaves are rich in tannins (a chemical compound) and flavonoids (a plant pigment), which both have antioxidant properties, according to research in Antioxidants journal. A 2017 study demonstrated that ellagic acid can inhibit pancreatic cancer growth. But what about the leaves?

article thumbnail

MDMA on track for 2023 approval as PTSD therapy, says developer

pharmaphorum

A medicine based on MDMA – the active ingredient in recreational drug ecstasy – is on the cusp of FDA approval as a treatment for post-traumatic stress disorder (PTSD), according to the organisation developing it. . A second is underway in 100 subjects and if positive could result in a green light for the therapy in 2023.

FDA 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Novartis’ radioligand therapy meets phase 3 prostate cancer trial target

pharmaphorum

The company said it plans to present data at an upcoming medical meeting and will include it in filings with the FDA and regulators in Europe. Radioligand therapy combines a targeting compound that binds to markers expressed by tumours with a radioactive isotope.

article thumbnail

Psychedelic research: evaluating the fast-evolving regulatory roadmap

European Pharmaceutical Review

Although some psychedelics have a long history in traditional medicine, regulatory agencies must evaluate psychedelic compounds the same way they assess any other drug. Psychedelic compounds are assessed by regulators the same way as any other drug. This US pathway offers early-phase benefits, including greater FDA collaboration.

article thumbnail

Clinical success begins early for small molecule drugs

European Pharmaceutical Review

Solving this before the clinical stage ensures the viability of compounds…” Addressing bioavailability challenges in the first phases of development is essential to help create the most robust product profile and increase the potential for success as small molecule drugs move to the clinic. amorphous solid dispersions, or ASDs.

article thumbnail

Can psychedelics provide breakthrough in mental health?

pharmaphorum

The term ‘psychedelic treatments’ incorporates a broad spectrum of different compounds, from LSD, psilocybin and DMT, to MDMA, ibogaine and ketamine. The latter compound has already been approved for treatment-resistance depression as the product Spravato (esketamine), after being developed by Janssen.

article thumbnail

3D printing and personalised medicines: embracing innovative technologies

Hospital Pharmacy Europe

Supporting the successful compounding of drugs with 3D printing processes has the potential to not only fulfil unmet patient needs but also drive efficiencies in hospital pharmacies. 2 The first drug produced through printing technology based on inkjet on powder was approved by the US FDA in 2015.

Hospitals 111